Prosensa Beats IPO Investors' Suit Over Failed Drug
A New York federal judge has dismissed a shareholder class action against Dutch biotech company Prosensa Holding NV over a stock drop following a clinical-trial failure for its crown-jewel drug, saying...To view the full article, register now.
Already a subscriber? Click here to view full article